HTG Molecular Diagnostics, Inc. (HTGM)
Stock Price:
$4.44 USD
-0.27 (-5.73%)
Updated November 24, 4:00 PM EST - Market closed
Key Info
| Market Cap |
21.04M |
| Revenue (ttm) |
10.77M |
| Net Income (ttm) |
-20.97M |
| Shares Out |
4.74M |
| EPS (ttm) |
-7.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 24 |
| Last Price |
$4.44 |
| Previous Close |
$4.71 |
| Change ($) |
-0.27 |
| Change (%) |
-5.73% |
| Day's Open |
4.64 |
| Day's Range |
4.05 - 4.65 |
| Day's Volume |
450,239 |
| 52-Week Range |
0.27 - 4.76 |
More Stats
| Market Cap |
21.04M |
| Enterprise Value |
3.07M |
| Earnings Date (est) |
Mar 25, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
4.74M |
| Float |
3.88M |
| EPS (basic) |
-0.25 |
| EPS (diluted) |
-7.64 |
| FCF / Share |
-0.24 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.73M |
| Short Ratio |
1.06 |
| Short % of Float |
44.53% |
| Beta |
1.69 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1.95 |
| PB Ratio |
1.27 |
| Revenue |
10.77M |
| Operating Income |
-19.88M |
| Net Income |
-20.97M |
| Free Cash Flow |
-17.37M |
| Net Cash |
17.98M |
| Net Cash / Share |
3.79 |
| Gross Margin |
-2.58% |
| Operating Margin |
-184.63% |
| Profit Margin |
-194.80% |
| FCF Margin |
-161.32% |
| ROA |
-28.35% |
| ROE |
-94.63% |
| ROIC |
-67.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
3 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$14.62*
(229.28% upside)
Low
6.00
Current: $4.44
High
22.50
Target: 14.62
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 19.20 | 21.50 | 14.76 | 5.13 | 4.04 | 3.33 | 2.24 |
| Revenue Growth | -10.7% | 45.69% | 187.56% | 27% | 21.41% | 48.41% | - |
| Gross Profit | 10.29 | 16.41 | 9.79 | 1.00 | 0.71 | 0.12 | - |
| Operating Income | -18.96 | -16.16 | -17.72 | -24.33 | -18.89 | -12.85 | -11.92 |
| Net Income | -19.30 | -16.45 | -18.96 | -26.04 | -21.40 | -13.96 | -11.77 |
| Shares Outstanding | 38.10 | 27.52 | 10.60 | 7.11 | 4.52 | 0.10 | 0.10 |
| Earnings Per Share | -0.51 | -0.60 | -1.79 | -3.66 | -5.03 | -175.03 | -147.48 |
| Operating Cash Flow | -16.70 | -13.17 | -16.57 | -22.23 | -19.24 | -13.00 | -11.82 |
| Capital Expenditures | -1.10 | -0.95 | -1.02 | -1.95 | -1.34 | -0.86 | -0.78 |
| Free Cash Flow | -17.80 | -14.12 | -17.59 | -24.18 | -20.58 | -13.85 | -12.60 |
| Cash & Equivalents | 36.30 | 31.11 | 9.97 | 11.81 | 31.50 | 3.61 | 1.82 |
| Total Debt | 11.25 | 9.68 | 8.75 | 11.78 | 10.80 | 10.52 | - |
| Net Cash / Debt | 25.05 | 21.43 | 1.21 | 0.03 | 20.70 | -6.91 | 1.82 |
| Assets | 45.12 | 43.77 | 21.26 | 18.45 | 39.39 | 8.73 | 4.40 |
| Liabilities | 21.15 | 22.68 | 24.32 | 24.05 | 22.50 | 22.48 | 11.78 |
| Book Value | 23.97 | 21.09 | -3.06 | -5.59 | 16.89 | -69.67 | -58.25 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
HTG Molecular Diagnostics, Inc. |
| Country |
United States |
| Employees |
108 |
| CEO |
John L. Lubniewski |
Stock Information
| Ticker Symbol |
HTGM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: HTGM |
| IPO Date |
May 6, 2015 |
Description
HTG Molecular Diagnostics a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.